or Try an Advanced Search...

    Technical Analysis for OGN - Organon & Co.

    Grade Last Price % Change Price Change
    F 14.55 -3.64% -0.55
    OGN closed up 0.47 percent on Monday, November 18, 2024, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical OGN trend table...
    Date Alert Name Type % Chg
    Oversold Stochastic Weakness -3.64%
    Oversold Stochastic Weakness -3.19%
    Oversold Stochastic Weakness -4.96%
    Slingshot Bearish Bearish Swing Setup -6.79%
    Oversold Stochastic Weakness -6.79%
    Gilligan's Island Buy Setup Bullish Swing Setup -6.61%
    Calm After Storm Range Contraction -6.61%
    Doji - Bullish? Reversal -6.61%
    Gapped Down Weakness -6.61%
    Oversold Stochastic Weakness -6.61%
    Older End-of-Day Signals for OGN ...

       Recent Intraday Alerts

    Alert Time
    Down 3% 18 minutes ago
    60 Minute Opening Range Breakdown 27 minutes ago
    Gap Down Partially Closed about 3 hours ago
    Fell Below Previous Day's Low about 3 hours ago
    Down 2 % about 3 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    OGN Chart by TradingView
    Basic chart:

    Profile

    Organon & Co., a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey. Organon & Co. operates independently of Merck & Co., Inc. as of June 2, 2021.
    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - General
    Keywords: Life Sciences Pharmaceutical Health Care Health Solutions Biosimilar

    Is OGN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 14 Organon: 7% Yield, 4x P/E, Big Upside Potential
    Nov 13 Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)
    Nov 8 Organon's (NYSE:OGN) Earnings Are Weaker Than They Seem
    Nov 5 Earnings Update: Organon & Co. (NYSE:OGN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
    Nov 5 Organon updates outlook as FDA delays VTAMA label expansion
    Nov 5 Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
    Nov 3 Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28
    Nov 1 Organon Third Quarter 2024 Earnings: EPS: US$1.39 (vs US$0.23 in 3Q 2023)
    Oct 31 Organon & Co. 2024 Q3 - Results - Earnings Call Presentation
    Oct 31 Organon & Co. (OGN) Q3 2024 Earnings Call Transcript
    See more OGN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 22.698
    52 Week Low 10.1994
    Average Volume 2,443,448
    200-Day Moving Average 18.69
    50-Day Moving Average 17.75
    20-Day Moving Average 16.43
    10-Day Moving Average 15.57
    Average True Range 0.53
    RSI (14) 28.57
    ADX 36.7
    +DI 13.58
    -DI 35.21
    Chandelier Exit (Long, 3 ATRs) 17.11
    Chandelier Exit (Short, 3 ATRs) 16.40
    Upper Bollinger Bands 18.36
    Lower Bollinger Band 14.51
    Percent B (%b) 0.15
    BandWidth 23.44
    MACD Line -0.76
    MACD Signal Line -0.67
    MACD Histogram -0.0878
    Fundamentals Value
    Market Cap 3.86 Billion
    Num Shares 256 Million
    EPS 2.28
    Price-to-Earnings (P/E) Ratio 6.62
    Price-to-Sales 0.68
    Price-to-Book 1.84
    Dividend 1.12
    Dividend Yield 7.42%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 15.63
    Resistance 3 (R3) 15.58 15.37 15.54
    Resistance 2 (R2) 15.37 15.23 15.39 15.51
    Resistance 1 (R1) 15.23 15.15 15.30 15.28 15.48
    Pivot Point 15.02 15.02 15.05 15.04 15.02
    Support 1 (S1) 14.88 14.88 14.95 14.93 14.72
    Support 2 (S2) 14.67 14.80 14.69 14.69
    Support 3 (S3) 14.53 14.67 14.66
    Support 4 (S4) 14.58